Charles River Laboratories International (NYSE:CRL) Given New $190.00 Price Target at JPMorgan Chase & Co.

Charles River Laboratories International (NYSE:CRL) had its target price raised by JPMorgan Chase & Co. from $165.00 to $190.00 in a report published on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the medical research company’s stock.

Several other brokerages have also commented on CRL. TD Cowen decreased their target price on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. William Blair upgraded shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Barclays upped their target price on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday, October 8th. Finally, Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target on the stock in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus target price of $194.07.

Charles River Laboratories International Stock Up 2.6%

Shares of Charles River Laboratories International stock opened at $197.97 on Monday. Charles River Laboratories International has a one year low of $91.86 and a one year high of $200.58. The company has a market cap of $9.74 billion, a P/E ratio of -126.90, a PEG ratio of 6.82 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37. The firm has a fifty day moving average of $177.86 and a two-hundred day moving average of $164.09.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business’s quarterly revenue was down .5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.59 earnings per share. On average, analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of large investors have recently bought and sold shares of the stock. Groupama Asset Managment acquired a new position in shares of Charles River Laboratories International in the third quarter worth $416,000. CIBC Bancorp USA Inc. purchased a new stake in Charles River Laboratories International during the 3rd quarter worth about $786,000. Danske Bank A S acquired a new position in Charles River Laboratories International in the 3rd quarter valued at about $4,070,000. Advisory Services Network LLC lifted its holdings in Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after purchasing an additional 83 shares in the last quarter. Finally, Castleark Management LLC acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter worth about $4,892,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).